This article is more than 5 years old. Information may no longer be current.

BioTime, Orbit Biomedical to collaborate on OpRegen subretinal delivery for dry AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular degeneration, according to a press release.

Under the terms of the exclusive 12-month agreement, the companies will collaborate on the use of Orbit’s injection technology to deliver BioTime’s OpRegen to the subretinal space via a suprachoroidal route in an ongoing phase 1/2 clinical study.

“Orbit Biomedical’s specifically designed device offers surgeons an innovative solution for the delivery of therapies to the subretinal space, a well-known challenge in ophthalmology,” BioTime CEO Brian M. Culley said in the release. “This alliance gives us the opportunity to evaluate the Orbit Biomedical technology early in the clinical development process of OpRegen and also provides BioTime with an option to negotiate an exclusive license for the commercial use of the device with OpRegen for the treatment of dry AMD.”